Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis

BACKGROUND: High-grade glioma (HGG) is a fatal human cancer. Bortezomib, a proteasome inhibitor, has been approved for the treatment of multiple myeloma but its use in glioma awaits further investigation. This study aimed to explore the chemotherapeutic effect and the underlying mechanism of bortezo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Commun (Lond)
Main Authors: Tang, Jun-Hai, Yang, Lin, Chen, Ju-Xiang, Li, Qing-Rui, Zhu, Li-Rong, Xu, Qing-Fu, Huang, Guo-Hao, Zhang, Zuo-Xin, Xiang, Yan, Du, Lei, Zhou, Zheng, Lv, Sheng-Qing
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2019
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6892143/
https://ncbi.nlm.nih.gov/pubmed/31796105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-019-0424-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares